# REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

Study · id `cardio:ct-nct07853716` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07853716](<https://clinicaltrials.gov/study/NCT07853716>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07853716

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT07853716. Randomized; no masking; primary purpose prevention. Start 2026-11 (anticipated); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT07853716, source copy `cardio:ctgov-nct07853716-2026-10-02`, retrieved 2026-10-26)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07853716, source copy `cardio:ctgov-nct07853716-2026-10-02`, retrieved 2026-10-26)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07853716, source copy `cardio:ctgov-nct07853716-2026-10-02`, retrieved 2026-10-26)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07853716, source copy `cardio:ctgov-nct07853716-2026-10-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07853716, source copy `cardio:ctgov-nct07853716-2026-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07853716-2026-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care
- Acronym: REFINE-CAC
- Condition: CAD - Coronary Artery Disease
- Intervention (Device): Heartflow Analysis
- Lead sponsor: HeartFlow, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Avania
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: HeartFlow, Inc. (`cardio:org-heartflow-inc`)
- Registry lists this organization as a collaborator: Avania (`cardio:org-avania`)

## Provenance

Content hash: 4ee7ae81e5ad7d50b5364832991cd63749f9100a99e43cdf41153ceb4d143db6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
